An open-label, single-center, phase 2 trial of a second-line therapy comprising low-dose decitabine (DAC) plus bortezomib (Bort) and dexamethasone (DXM) (Dvd) in relapsed and/or refractory multiple myeloma (RRMM) patients was conducted to screen available and inexpensive agents, aiming to work synergistically with other existing anti-melanoma drugs at reasonable prices, and effectively treat Bort and/or Len-refractory patients. Forty-seven patients were included according to the inclusion criteria, with only 1 withdrawal due to premature death. After 17.2 (range: 0.5-24.1) months of median follow-up, all the 46 cases had halted or completed DVd therapy per protocol, with an overall response rate (ORR) of 87.0%. Meanwhile, DVd was indicated to induce high, deep, and lasting responses, dependent of prior treatment or baseline characteristics. The results revealed that DVd is well-tolerated and highly effective in the treatment of first-relapsed RRMM (including those with Bort-refractory disease) patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164821 | PMC |
Publication Analysis
Top Keywords
Similar Publications
5-Aza-2'-deoxycytidin (Decitabine) increases cancer-testis antigen expression in head and neck squamous cell carcinoma and modifies immune checkpoint expression, especially in CD39-positive CD8 and CD4 T cells.
Neoplasia
January 2025
Head and Neck Cancer Center of the Comprehensive Cancer Center, Department of Otorhinolaryngology and Head & Neck Surgery, Ulm University Medical Center, Germany; Ulm University Medical Faculty, Core Facility Immune Monitoring, Ulm, Germany. Electronic address:
Failure of immunotherapy in head and neck squamous cell carcinoma (HNSCC) patients represents an unmet need to augment leverage of adaptive immunity. Immunogenic cancer-testis antigen (CTA) expression as well as lymphocyte differentiation and function are regulated by DNA methylation. Therefore, epigenetic therapy via inhibition of DNA-Methyltransferases by 5-Aza-2'-deoxycytidine (DAC) serves a promising adjuvant in immunotherapy.
View Article and Find Full Text PDFSingle low-dose decitabine as frontline therapy of acute myeloid leukaemia, with venetoclax salvage.
J Cell Mol Med
October 2024
Research Center for Advanced Medicine MedFUTRE, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.
Blood
November 2024
Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY.
Article Synopsis
- - A study found that a low-dose regimen of decitabine and venetoclax was both safe and effective for treating myeloid cancers in an older, diverse group with minimal need to reduce or pause treatment.
- - Patients with acute myeloid leukemia who had a TP53 mutation had a median overall survival of 16.1 months, while those without the mutation had an overall survival of 11.3 months.
- - This clinical trial is officially registered at www.clinicaltrials.gov under the identifier #NCT05184842.
Decitabine-based treatment strategy improved the outcome of HSCT in JMML: a retrospective cohort study.
Front Immunol
September 2024
Nanfang-Chunfu Children's Institute of Hematology & Oncology, TaiXin Hospital, Dongguan, China.
Introduction: Pre-HSCT disease control, suboptimal long-term prognosis, and a high recurrence incidence (RI) continue to pose significant challenges for hematopoietic stem cell transplantation (HSCT) in juvenile myelomonocytic leukemia (JMML) patients.
Methods: This retrospective cohort study assessed the effectiveness of a decitabine (DAC)-based protocol in JMML patients undergoing HSCT. The pre-HSCT treatment includes initial and bridging treatment.
A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis.
Blood Adv
November 2024
Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL.
Myelofibrosis (MF) in the chronic phase is a challenging disease to treat, and conventional treatment options are geared toward symptom palliation. In this prospective, multicenter, phase 2 trial, 21 patients with MF (18 chronic phase, 2 accelerated phase, and 1 blast phase) were treated with a 10-day schedule of subcutaneous decitabine at 0.3 mg/kg per day.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!